Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2

Inclusion criteria

• . Participants from the NTMT-03 study must have completed the Month-24 visit
• . Participant in the MacTel Phase 1/2 extension (NTMT-01/02E) study or the Phase 3 study must exit these studies prior to entering the Bilateral Implant safety study (NTMT-02B)
• . Participant must be willing and able to follow the study instructions and be willing and able to complete all required study procedures and visits
• . Participant must be willing and able to provide a signed Informed Consent, as well as written documentation in accordance with the relevant country and local privacy requirements, e.g., written data protection consent
• . Females of childbearing potential must consent to a pregnancy test before entering the study
• . A participant's refusal to allow the collection of blood samples for analysis of serum CNTF, serum Ab or Nab to CNTF, Ab to NTC-201.6A cells and Ab to DFHR levels in one eye will not exclude the participant from study participation
• . Participant must have a positive diagnosis of MacTel type 2 with evidence of fluorescein leakage typical of MacTel and at least one of the other features that include hyperpigmentation that is outside of a 500-micron radius from the center of the fovea, retinal opacification, crystalline deposits, right-angle vessels, or inner/outer lamellar cavities in the study eye
• . Participant must have steady fixation in the foveal or parafoveal area in the study eye and sufficiently clear media for good quality photographs

Exclusion criteria